Další formáty:
BibTeX
LaTeX
RIS
@article{1531317,
author = {Barczi, Eniko and Starobinski, Livia and KolonicsandFarkas, Abigel and Eszes, Noemi and Bohacs, Aniko and Vasakova, Martina and Hejduk, Karel and Muller, Veronika},
article_location = {NEW YORK},
article_number = {5},
doi = {http://dx.doi.org/10.1007/s12325-019-00906-9},
keywords = {IPF; Nintedanib; Pharmacotherapy; Respiratory; pulmonary; Safety; Severe IPF; Survival},
language = {eng},
issn = {0741-238X},
journal = {ADVANCES IN THERAPY},
title = {Long-Term Effects and Adverse Events of Nintedanib Therapy in Idiopathic Pulmonary Fibrosis Patients with Functionally Advanced Disease},
url = {http://dx.doi.org/10.1007/s12325-019-00906-9},
volume = {36},
year = {2019}
}
TY - JOUR
ID - 1531317
AU - Barczi, Eniko - Starobinski, Livia - Kolonics-Farkas, Abigel - Eszes, Noemi - Bohacs, Aniko - Vasakova, Martina - Hejduk, Karel - Muller, Veronika
PY - 2019
TI - Long-Term Effects and Adverse Events of Nintedanib Therapy in Idiopathic Pulmonary Fibrosis Patients with Functionally Advanced Disease
JF - ADVANCES IN THERAPY
VL - 36
IS - 5
SP - 1221-1232
EP - 1221-1232
PB - SPRINGER
SN - 0741238X
KW - IPF
KW - Nintedanib
KW - Pharmacotherapy
KW - Respiratory
KW - pulmonary
KW - Safety
KW - Severe IPF
KW - Survival
UR - http://dx.doi.org/10.1007/s12325-019-00906-9
L2 - http://dx.doi.org/10.1007/s12325-019-00906-9
N2 - IntroductionIdiopathic pulmonary fibrosis (IPF) is one of the most common interstitial lung diseases with limited survival. The effect of IPF therapy in patients with severely impaired lung function is not well established. The aim of this study was to characterize IPF patients with a forced vital capacity (FVC)<50% (group 1) and FVC 50-60% predicted (group 2) and analyze the effect and adverse events of nintedanib in Hungarian patients diagnosed between April 2015 and July 2017.MethodsThe impact of nintedanib therapy on lung function, survival, and adverse events was analyzed longitudinally.ResultsTwenty-two out of 103 patients were included in the analysis (group 1: N=10; male/female=6:4, age 62.610.8years and group 2: N=12; male/female=3:9, age 65.7 +/- 11.6years). Eighteen patients were treated with nintedanib (8 in group 1, 10 in group 2); treatment stabilized lung function in 42% and 50%, respectively, in the two groups. Median survival was 444days for group 1 and 476days for group 2. Adverse events were less common than in clinical trials; dose reduction was necessary in three cases, drug discontinuation in two cases. No differences between groups were identified regarding clinical parameters and radiological pattern; however, hypertension as comorbidity was more common in group 1 patients.Conclusions Nintedanib therapy was effective and well tolerated even among patients with severely impaired lung function. Longitudinal follow-up confirmed high mortality in patients with very severe and severe IPF; however, median survival was meaningful as it exceeded 1year in both groups.
ER -
BARCZI, Eniko, Livia STAROBINSKI, Abigel KOLONICS-FARKAS, Noemi ESZES, Aniko BOHACS, Martina VASAKOVA, Karel HEJDUK a Veronika MULLER. Long-Term Effects and Adverse Events of Nintedanib Therapy in Idiopathic Pulmonary Fibrosis Patients with Functionally Advanced Disease. \textit{ADVANCES IN THERAPY}. NEW YORK: SPRINGER, 2019, roč.~36, č.~5, s.~1221-1232. ISSN~0741-238X. Dostupné z: https://dx.doi.org/10.1007/s12325-019-00906-9.
|
